| CIML NK Cell in Head & Neck Cancer (NCT04290546) | Dana-Farber Cancer Institute | 2020-07-20 |
| LY3214996 in Patients With AML Who Are Not Candidates for Standard Therapy (NCT04081259) | Dana-Farber Cancer Institute | 2020-07-15 |
| MARGetuximab Or Trastuzumab (MARGOT) (NCT04425018) | Dana-Farber Cancer Institute | 2020-07-13 |
| Ibrutinib + Venetoclax in Untreated WM (NCT04273139) | Dana-Farber Cancer Institute | 2020-07-09 |
| Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA) (NCT04434040) | Dana-Farber Cancer Institute | 2020-07-02 |
| Tucatinib + Abemaciclib + Herceptin for HER2+ MBC (NCT03846583) | Dana-Farber Cancer Institute | 2020-06-28 |
| Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT (NCT03777982) | Dana-Farber Cancer Institute | 2020-04-20 |
| Advance Care Planning: Promoting Effective and Aligned Communication in the Elderly (NCT03609177) | Dana-Farber Cancer Institute | 2020-04-15 |
| ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies (NCT04043845) | Dana-Farber Cancer Institute | 2020-02-03 |
| GVAX Plus Checkpoint Blockade in Neuroblastoma (NCT04239040) | Dana-Farber Cancer Institute | 2020-01-29 |
| Ex Vivo TCR αβ T Cell Depletion for Graft-Versus-Host Disease Prophylaxis in Mismatched Donor Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies (NCT03717480) | Dana-Farber Cancer Institute | 2020-01-21 |
| Serial MRI Scans During Radiation Therapy (NCT04188535) | Dana-Farber Cancer Institute | 2020-01-15 |
| A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC) (NCT03835819) | Dana-Farber Cancer Institute | 2020-01-02 |
| Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions (NCT04071756) | Dana-Farber Cancer Institute | 2019-12-30 |
| Cabozantinib and Nivolumab for Carcinoid Tumors (NCT04197310) | Dana-Farber Cancer Institute | 2019-12-26 |
| OPTimizing Treatment Focused Genetic Testing IN Cancer (NCT04066361) | Dana-Farber Cancer Institute | 2019-12-19 |
| Videos for Advance Care Planning in Young Adults (NCT04149704) | Dana-Farber Cancer Institute | 2019-12-13 |
| A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma (NCT04045470) | Dana-Farber Cancer Institute | 2019-12-11 |
| Palbociclib + Ganitumab In Ewing Sarcoma (NCT04129151) | Dana-Farber Cancer Institute | 2019-12-05 |
| Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression (NCT04040725) | Dana-Farber Cancer Institute | 2019-11-27 |
| Smart Phone App Intervention In Young Adults With Cancer (NCT04119869) | Dana-Farber Cancer Institute | 2019-11-11 |
| Stereotactic Magnetic Resonance Guided Radiation Therapy (NCT04115254) | Dana-Farber Cancer Institute | 2019-10-22 |
| Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (NCT03936465) | Dana-Farber Cancer Institute | 2019-09-27 |
| The Value of Advanced MR Imaging in Gynecological Tumors and Benign Uterine Fibroids (NCT03993210) | Dana-Farber Cancer Institute | 2019-09-18 |
| A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma (NCT04007588) | Dana-Farber Cancer Institute | 2019-09-06 |
| A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (NCT04024761) | Dana-Farber Cancer Institute | 2019-08-31 |
| Yoga for Painful Chemotherapy-Induced Peripheral Neuropathy: A Pilot, Randomized-Controlled Study (NCT03824860) | Dana-Farber Cancer Institute | 2019-08-06 |
| A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma (NCT03999684) | Dana-Farber Cancer Institute | 2019-08-05 |
| Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts (NCT03974217) | Dana-Farber Cancer Institute | 2019-08-01 |
| Symptom Management Implementation of Patient Reported Outcomes in Oncology (NCT03850912) | Dana-Farber Cancer Institute | 2019-07-25 |
| Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy (NCT03761160) | Dana-Farber Cancer Institute | 2019-07-16 |
| A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT (NCT03912064) | Dana-Farber Cancer Institute | 2019-07-10 |
| Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer (NCT03894891) | Dana-Farber Cancer Institute | 2019-06-11 |
| A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas (NCT03899805) | Dana-Farber Cancer Institute | 2019-06-04 |
| Pilot Feasibility of the Pediatric Cancer Resource Equity (PediCARE) Intervention (NCT03638453) | Dana-Farber Cancer Institute | 2019-05-28 |
| Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot (NCT03913936) | Dana-Farber Cancer Institute | 2019-05-23 |
| Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma (NCT03875716) | Dana-Farber Cancer Institute | 2019-05-20 |
| Individualizing Surveillance Mammography for Older Breast Cancer Survivors (NCT03865654) | Dana-Farber Cancer Institute | 2019-05-16 |
| GENetic Education Risk Assessment and TEsting Study (NCT03762590) | Dana-Farber Cancer Institute | 2019-05-08 |
| The PRISM Intervention: a Multi-site Randomized Controlled Trial for Adolescents and Young Adults With Advanced Cancer (NCT03668223) | Dana-Farber Cancer Institute | 2019-04-15 |
| Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer (NCT03749421) | Dana-Farber Cancer Institute | 2019-03-21 |
| 'ADVANCE' (A Pilot Trial) (NCT03858322) | Dana-Farber Cancer Institute | 2019-03-21 |
| Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency (NCT03716739) | Dana-Farber Cancer Institute | 2019-03-19 |
| EHR-embedded OCDT in Breast or GI Cancer (NCT03858712) | Dana-Farber Cancer Institute | 2019-03-13 |
| NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer (NCT03789110) | Dana-Farber Cancer Institute | 2019-03-08 |
| GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases (NCT03765983) | Dana-Farber Cancer Institute | 2019-02-25 |
| Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain (NCT03910296) | Dana-Farber Cancer Institute | 2019-02-20 |
| A Feasibility Study of Durvalumab +/- Oleclumab as Neoadjuvant Therapy for Muscle-invasive Bladder Cancer (BLASST-2) (NCT03773666) | Dana-Farber Cancer Institute | 2019-02-20 |
| Elevate! : An Elderly Breast Cancer Cohort Study (NCT03818087) | Dana-Farber Cancer Institute | 2019-02-19 |
| Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL (NCT03740334) | Dana-Farber Cancer Institute | 2019-01-30 |
| Mindfulness-Music Intervention for Adolescents and Young Adults With Cancer (NCT03709225) | Dana-Farber Cancer Institute | 2019-01-22 |
| Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial (NCT03735446) | Dana-Farber Cancer Institute | 2019-01-18 |
| Acupuncture for Hot Flashes in Hormone Receptor-Positive Breast Cancer, a Randomized Controlled Trial (NCT03783546) | Dana-Farber Cancer Institute | 2019-01-15 |
| RESOLVE: Abemaciclib + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer (NCT03675893) | Dana-Farber Cancer Institute | 2018-12-24 |
| Avelumab and Radiation in Muscle-Invasive Bladder Cancer (NCT03747419) | Dana-Farber Cancer Institute | 2018-12-13 |
| Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia (NCT03692325) | Dana-Farber Cancer Institute | 2018-12-05 |
| Paricalcitol Plus Gemcitabine and Nab-paclitaxel in Metastatic Pancreatic Cancer (NCT03520790) | Dana-Farber Cancer Institute | 2018-12-05 |
| An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma (NCT03227432) | Dana-Farber Cancer Institute | 2018-12-01 |
| Sexual Health and Rehabilitation After Ovarian Suppression Treatment (NCT03571841) | Dana-Farber Cancer Institute | 2018-12-01 |
| Testing Feasibility of Motivational Interviewing for Patient-Reported Cancer Pain Goals (NCT03736746) | Dana-Farber Cancer Institute | 2018-11-16 |
| Mathematical Model-Adapted Radiation In Glioblastoma (NCT03557372) | Dana-Farber Cancer Institute | 2018-11-12 |
| DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC (NCT03716180) | Dana-Farber Cancer Institute | 2018-11-05 |
| Smartphone Technology to Alleviate Malignant Pain (STAMP) (NCT03717402) | Dana-Farber Cancer Institute | 2018-11-01 |
| Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer (NCT03654716) | Dana-Farber Cancer Institute | 2018-11-01 |
| Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers (NCT03683680) | Dana-Farber Cancer Institute | 2018-10-31 |
| Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) (NCT03689595) | Dana-Farber Cancer Institute | 2018-10-31 |
| Rituximab + Immunotherapy in Follicular Lymphoma (NCT03636503) | Dana-Farber Cancer Institute | 2018-10-30 |
| AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma (NCT03668340) | Dana-Farber Cancer Institute | 2018-10-22 |
| Peri-Transfusion QOL Assessments (PTQA): A New Paradigm of Transfusion Decision Support for Patients With MDS (NCT03660228) | Dana-Farber Cancer Institute | 2018-10-17 |
| Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML (NCT03709758) | Dana-Farber Cancer Institute | 2018-10-17 |
| Olaparib + Sapacitabine in BRCA Mutant Breast Cancer (NCT03641755) | Dana-Farber Cancer Institute | 2018-10-01 |
| Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma (NCT03661723) | Dana-Farber Cancer Institute | 2018-09-28 |
| Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue (NCT03657628) | Dana-Farber Cancer Institute | 2018-09-17 |
| MCS110 With BRAF/MEK Inhibition in Patients With Melanoma (NCT03455764) | Dana-Farber Cancer Institute | 2018-09-10 |
| EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options (NCT03602885) | Dana-Farber Cancer Institute | 2018-09-01 |
| Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) (NCT03485547) | Dana-Farber Cancer Institute | 2018-08-23 |
| Niraparib in Patients With Pancreatic Cancer (NCT03601923) | Dana-Farber Cancer Institute | 2018-08-22 |
| ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer (NCT03587740) | Dana-Farber Cancer Institute | 2018-08-22 |
| Osimertinib In EGFR Mutant Lung Cancer (NCT03586453) | Dana-Farber Cancer Institute | 2018-08-13 |
| Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors (NCT03279055) | Dana-Farber Cancer Institute | 2018-08-10 |
| Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (NCT03580928) | Dana-Farber Cancer Institute | 2018-08-07 |
| Prospective Study of BK Virus Disease After Allogeneic Hematopoietic-cell Transplantation: Defining BK Disease's Natural History, Clinical Spectrum, Immunology, and Outcomes (NCT03532971) | Dana-Farber Cancer Institute | 2018-07-30 |
| SHARE (Sharing Goals and Preferences) Study (NCT03392090) | Dana-Farber Cancer Institute | 2018-07-23 |
| Stepping Into Survivorship: Harnessing Behavioral Economics to Improve Quality of Life in Ovarian Cancer (NCT03364673) | Dana-Farber Cancer Institute | 2018-07-20 |
| Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS (NCT03534323) | Dana-Farber Cancer Institute | 2018-07-12 |
| The GI Binder: A Psychoeducational Intervention for Gastrointestinal Cancer Patients (NCT03576872) | Dana-Farber Cancer Institute | 2018-07-09 |
| Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy (NCT03514680) | Dana-Farber Cancer Institute | 2018-06-04 |
| Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer (NCT03277482) | Dana-Farber Cancer Institute | 2018-06-01 |
| A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors (NCT03495323) | Dana-Farber Cancer Institute | 2018-05-16 |
| Role of Contrast Enhanced Spectral Mammography to Predict Upgrade Rates of Biopsy Proven Atypical Ductal Hyperplasia (NCT03505372) | Dana-Farber Cancer Institute | 2018-05-10 |
| Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD (NCT06068075) | Dana-Farber Cancer Institute | 2018-05-08 |
| Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis (NCT03483012) | Dana-Farber Cancer Institute | 2018-05-01 |
| Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor (NCT03239145) | Dana-Farber Cancer Institute | 2018-05-01 |
| BOLSTER: Building Out Lifelines for Safety, Trust, Empowerment and Renewal (NCT03367247) | Dana-Farber Cancer Institute | 2018-04-24 |
| Study of Pancreatic Enzyme Replacement on Completion of Adjuvant Chemotherapy for Resected Pancreatic Adenocarcinoma (NCT03469258) | Dana-Farber Cancer Institute | 2018-04-13 |
| Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC (NCT03425331) | Dana-Farber Cancer Institute | 2018-04-10 |
| Study of Radiation Fractionation on Patient Outcomes After Breast REConstruction (FABREC) for Invasive Breast Carcinoma (NCT03422003) | Dana-Farber Cancer Institute | 2018-04-01 |
| A Phase II Study of BVD-523 in Metastatic Uveal Melanoma (NCT03417739) | Dana-Farber Cancer Institute | 2018-03-26 |
| Neodjuvant Nivolumab and Lirilumab, Followed by Surgery, Followed by Adjuvant Nivolumab and Lirilumab, in SCCHN (NCT03341936) | Dana-Farber Cancer Institute | 2018-03-15 |
| Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds (NCT03447886) | Dana-Farber Cancer Institute | 2018-03-09 |